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ABSTRACT
Pharmaceuticals are designed to interact with spe-
cific molecular targets in humans and these targets
generally have orthologs in other species. This pro-
vides opportunities for the drug discovery commu-
nity to use alternative model species for drug de-
velopment. It also means, however, there is poten-
tial for mode of action related effects in non-target
wildlife species as many pharmaceuticals reach the
environment through patient use and manufactur-
ing wastes. Acquiring insight in drug target ortholog
predictions across species and taxonomic groups
has proven difficult because of the lack of an opti-
mal strategy and because necessary information is
spread across multiple and diverse sources and plat-
forms. We introduce a new research platform tool,
ECOdrug, that reliably connects drugs to their pro-
tein targets across divergent species. It harmonizes
ortholog predictions from multiple sources via a sim-
ple user interface underpinning critical applications
for a wide range of studies in pharmacology, ecotox-
icology and comparative evolutionary biology. ECO-
drug can be used to identify species with drug targets
and identify drugs that interact with those targets. As
such, it can be applied to support intelligent targeted
drug safety testing by ensuring appropriate and rel-
evant species are selected in ecological risk assess-
ments. ECOdrug is freely accessible and available at:
http://www.ecodrug.org.
INTRODUCTION
Drug discovery scientists screen and design pharmaceuti-
cals based on their ability to interact with specific molecular
targets in humans. The therapeutic dosing regimen is opti-
mized for treatment efficacy while minimizing the risk of
side effects caused by off-target interactions. The pharma-
ceutical industry invests huge resources into testing drugs,
and non-human model species are an essential part of drug
development, as many have the same targets. On the other
hand, high evolutionary conservancy of drug targets means
that upon release of pharmaceuticals to the environment,
through patient use, manufacturing and inappropriate dis-
posal of unused medicines, there is potential for therapeutic
mode of action-related effects on wildlife species (1–3).
Understanding the conservation of human drug targets
across species has applications in drug discovery, environ-
mental protection and more generally in comparative phys-
iology and evolutionary biology research. For example, in
drug discovery the identification of appropriate orthologs
in model species may allow for faster and more cost effec-
tive screening of drugs in a developmental pipeline (4–6).
For any newmarket registration of medical products, in Eu-
rope and elsewhere (7,8), it is mandatory to perform an en-
vironmental risk assessment (ERA) which can involve envi-
ronmental toxicological studies. Knowledge of drug target
conservation can ensure that the most appropriate species
are selected. In addition, by identifying taxonomic groups
that lack a drug target unnecessary animal testing can be
avoided.
To date, it has been difficult to acquire accurate insights
on drug targets and their evolutionary conservation because
the necessary information is not in a single repository and
thus has to be retrieved from diverse sources. There are var-
ious datasets/databases that contain links between drugs
and human protein targets e.g. Drugbank (9–11). But these
sources do not cover the conservation of drug targets in a
wide range of non-human species. Santos et al. (10) presents
Ensembl ortholog predictions but this is limited to only 10
species. SeqAPASS is another resource that offers predic-
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Figure 1. Schematic of the ECOdrug data sources and features. Information on drugs and associated targets (9) was combined with ortholog predictions
(19–21) that can be accessed through the ECOdrug application.
tions of potential for chemicals to bind to targets in non-
human species (12), but this system relies on less well de-
veloped methods for ortholog prediction and is password
protected, limiting public access.
Establishing an evolutionary relationship between hu-
man drug target and non-human target is key as evolu-
tionary related genes like orthologs are typically the most
similar genes in the respective species in terms of sequence,
structure and function (13)––providing the highest likeli-
hood for a similar pharmacological effect to occur. Identi-
fication of orthologous relationships between genes is not a
trivial undertaking as the true evolutionary relationships of
genes are not known and need to be inferred from sequence
data. There is no single strategy to predict orthology be-
tween human genes and those present in non-mammalian
species and ortholog prediction is currently neither stan-
dardized nor optimized. Instead, a wide range of meth-
ods have been suggested, each with different strengths and
weaknesses (14,15). Furthermore, predictions need to be
updated on a regular basis, ideally concurrently with the re-
lease of new genomes and improvements in annotation of
existing genomes as a static dataset will lose value over time.
Here we present ECOdrug (http://www.ecodrug.org), a
user-friendly resource that provides an overview of inno-
vative and legacy drugs, their human drug targets and the
evolutionary conservation of these targets across taxonomic
groups. It has been shown that combining of multiple or-
tholog prediction approaches can improve predictions of
benchmarking datasets (16–18). Thus, to ensure an accurate
prediction of orthologous genes, even across species that are
evolutionary distant to one another, ECOdrug combines
three well established methods for the ortholog predictions:
Ensembl (19), EggNOG (20) and InParanoid (21). Impor-
tantly, we transparently show where the methods agree and
disagree. The database is an integrated platform that allows
for searches on drugs and/or drug targets and provides both
high-level overviews of drug-target conservation and infor-
mation of orthologs predicted in specific species.We provide
examples of howECOdrug can be used to select appropriate
species for drug design or environmental tests and to facil-
itate the generation of testable hypotheses regarding phar-
macologically related effects in wildlife species. We envisage
that the database will provide a valuable resource for en-
vironmental toxicology, drug discovery and development,
and safety communities by helping evaluate possibilities for
read across of effect data from humans to wildlife and from
model organisms to humans, as well as for research more
widely for studies in comparative physiology and evolution-
ary biology.
DATABASE CONTENT
ECOdrug was built to provide a resource for obtaining
information on drugs, their targets and associated or-
tholog predictions, currently for 640 eukaryotic species. The
database combines data from multiple sources and illus-
trates the confidence of the ortholog predictions through a
user friendly interface. An overview of the data sources and
features of ECOdrug is shown in Figure 1.
Data collection
Pharmaceuticals and their associated drug targets.
ECOdrug contains 1 194 Active Pharmaceutical In-
gredients (APIs)––targeting 663 proteins sourced from the
most recently published comprehensive map of molecular
targets to which the approved drugs bind and are responsi-
ble for the therapeutic efficacy of the drug (10). The human
target proteins are defined by their UniProt identifiers and
we use biomaRt (22) to retrieve the associated Ensembl
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Figure 2. Species coverage of predictions methods. (A) Each ortholog prediction method covers a different set of species. The overlap occurring between
the methods are indicated by the numbers in the Venn diagram. (B) The taxonomic tree provides an overview of the species representation in the dataset.
The number of species in taxonomic groups is indicated, with the numbers in black representing the total number of species, numbers in green illustrating
the number of species shared among all three prediction methods and red is used where there are no shared species in the group. The colors of the species
shades indicate larger taxonomic groups. Maroon/red: terrestrial vertebrates, gray: teleost fish, purple: invertebrate deuterostomes, orange: protostomes,
blue: fungi, dark green: viridiplantae.
gene (n = 708) and Ensembl protein identifiers (n = 1
718). In addition to drug targets, the dataset also includes
the following information on the APIs; therapeutic area,
indicated by anatomical therapeutic chemical (ATC) codes
(23), drug type (e.g. small molecule or protein) and associ-
ated mode(s) of action (10). Links to other databases such
as DrugBank (9), UniProt (24) and Ensembl (19) enables
users to quickly navigate to these sources, if desired.
Ortholog predictions. To obtain accurate ortholog predic-
tions, ECOdrug aggregates predictions from three sources:
Ensembl (19), EggNOG (20) and InParanoid (21). ECO-
drug retrieves Ensembl orthologs by mapping ensembl gene
IDs to all available ensembl homology attributes (data
for first ECOdrug version, from February 2017). Beyond
chordates the ortholog predictions are retrieved from En-
sembl panCompara (ECOdrug initially uses release 30)
(25). EggNOG ortholog predictions are retrieved by iter-
ating over EggNOGs taxonomic levels from the closest to
Homo sapiens (Hominidae NOG) to those most distant
(Eukaryotes NOG). Orthologs to human drug targets in a
given species were retrieved from the nearest possible taxo-
nomic level. For InParanoid 8.0 (21) predictions we applied
the standalone software package to derive orthologs be-
tween theHomo sapiensUniProt reference proteome (Initial
ECOdrug predictions based on UP000005640 9606.fasta;
UniProt Release 2016 04, Ensembl release 84 and Ensembl
Genome release 31) and other reference proteomes available
in the UniProt database. Sequence identity between drug
targets and predicted orthologs were calculated using global
alignment implemented in EMBOSS Needle (26). The or-
tholog predictions for Ensembl and EggNOG will be up-
dated four times per year, while predictions for InParanoid
are to be updated on an annual basis ensuring that the pre-
dictions will continue to be strengthened with new species,
new gene builds and improved predictions.
ECOdrug currently contains ortholog predictions for 640
species. However, species coverage differs for the available
ortholog prediction methods. Predictions for 63 species de-
rived from all three methods, and a further 136 species are
represented in at least two prediction methods (Figure 2A).
Mammals represent one third of the species that share pre-
dictions between the three methods, whereas some other
taxonomic clades, e.g. molluscs, do not have any shared
species (Figure 2B), reflecting both the significant knowl-
edge gaps and the focus of the scientific community. For
species present in multiple databases we combined predic-
tions on amajority vote principle, i.e. two ormore databases
have to agree on the presence/absence of a drug target or-
tholog in a species. In cases where a species is represented
in only two methods, majority vote calls presence of an or-
tholog if at least one database predicts an ortholog. The pre-
sentation in ECOdrug makes clear how many ortholog pre-
diction methods support any given majority vote.
For each method the ortholog predictions are stored in
.csv files, that can be downloaded through the ECOdrug ap-
plication.
Patterns in drug target ortholog predictions
Agreement on ortholog presence and absence. There was
substantial agreement on the presence/absence of orthologs
in species shared across the three databases (Figure 3A)
with the tendency for increasing uncertainty for predictions
with increasing taxonomic distance from humans. There
was an agreement across the three databases for at least 76%
of drug targets in vertebrates and around 65% for inverte-
brates, plants and algae. For fungi there was greater than
an 83% agreement across the three databases which reflects
the high quality fungal genome annotations and assemblies
that have been developed by a large research community.
The identity of drug targets with different results across the
predictions methods varies across species and taxa. In other
words, there is not a set of ‘contentious’ drug targets of
which predictions of presence/absence of an ortholog in a
species is always inconsistent across methods (Figure 3B).
Drug target conservation patterns in taxonomic space.
Mammalian species had the highest predicted number of
human drug target orthologs, on average 92% of the targets
had orthologs across the 23 species shared amongst all three
prediction methods (Figure 4). Within the non-mammalian
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Figure 3. Agreement in ortholog predictions. (A) Bar colors indicate the agreement on presence/absence of drug target orthologs. The color of the species
label indicates the taxonomic group (see Figure 2). (B) Histogram of the number of species with an ortholog prediction disagreement for drug targets. Circles
indicate how many drug targets fit in each 5% bin. Line colors indicate which species are included in the histogram with only species shared by Ensembl,
EggNOG and InParanoid being considered. Red: mammalian species, orange: vertebrate species, green: metazoan species, black: all shared species.
Figure 4. Drug target conservation in taxonomic groups. Bars indicate the
percentage of drug targets that have a predicted orthologs in a taxonomic
group. Ortholog conservation and standard deviation are shown for both
the shared species (left bar) and all species (right bar) in a taxonomic group.
vertebrates (birds, reptiles and fish) there were similar levels
of drug target conservation. In the invertebrate deuteros-
tomes including the tunicate Ciona intestinalis and the sea
urchin Strongylocentrotus purpuratus and in protostomes,
there were orthologs to 50–65% of the human drug targets.
Only the most evolutionary conserved genes might be ex-
pected to have orthologs in species in non-metazoan taxa
such as fungi, plants and algae. In species in these taxa
around 20–25% of the drug targets had predicted orthologs.
This pattern of orthologs across the different taxa supports
previously published results based on smaller scale assess-
ments (10,27). We also analyzed drug target conservation
across therapeutic space, showing that for drugs belong-
ing to certain ATC classes conservation patterns are always
identical (see Supplementary Materials File 1 and 2).
FEATURES
The ECOdrug user interface includes one tab for drug re-
lated information and one tab for drug targets. The drug
page (Supplementary Figure S2) has a search bar that al-
lows searches for any drug name or DrugBank identifier.
Users can view generic information on the drug, includ-
ing a general description, drug type, ATC code and de-
scription of the mode of action. A table is provided that
shows the drug targets of the selected drug and provides
a high level overview of conservation for each drug target.
In addition to the high level overview, a species level view
of drug target conservation is available for all species, or
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a particular subset (e.g. only mammals). For majority vote
presence/absence is indicated by TRUE/FALSE, whereas
for individual databases the identifier (Ensembl gene id, En-
sembl protein id or UniProt ID) and link to the external
databases are provided. Sequence identities are displayed in
brackets.
The drug target page (Figure 5) has a search function-
ality that accepts HGNC symbols, UniProt IDs, ensembl
gene IDs and ensembl peptide IDs. The application will
display a short description of the target, including links to
all drugs that target the selected protein. An overview of
the drug target conservation is visualized in a taxonomic
tree, based on species shared by all three databases. In the
same way as for the drug information page, the drug target
page offers a table for species level predictions with Latin
names, common names, NCBI taxonomy IDs, the number
of databases wherein a species is represented and the major-
ity vote/EggNOG/Ensembl/InParanoid predictions.
CASE STUDIES
Here we provide three examples of the application of ECO-
drug to: (i) identify appropriate model fish species for test-
ing a drug class; (ii) selecting appropriate invertebrate test
species for ERA and (iii) selecting appropriate species for
the environmental protection of primary producers.
Case study I: identifying appropriate model fish species
Protein pump inhibitors such as Omeprazole, Dexlansopra-
zole and Esomeprazole are used in the therapy for stomach
ulcers and act to block the H+/K+-ATPase proton pump
(ATP4A) that is responsible the acidic conditions in the
stomach. It has previously been shown that the presence of
a gastric stomach phenotype correlates with the presence of
ATP4A (28). In the first case study we applied ECOdrug to
look for potential orthologs in fish for the target to proton
pump inhibitors by selecting the drug target, ATP4A, and
teleostei as the taxonomic group on the Drug Target page.
The drug target page in ECOdrug illustrates that only 5 of
the 11 fish teleost species listed have orthologs to ATP4A
and these results agree with the pattern of conservation
of ATP4A, as presented by Castro et al. (28) (see Supple-
mentary Tables S1 and 2). Reliance on a single ortholog
database, in this instance EggNOG, would have resulted in
a false positive prediction as this database included a wider
group of ATPase transporters as orthologs of ATP4A, reaf-
firming themerit of combiningmultiple predictionmethods
to best ensure accuracy.
Case study II: Selecting appropriate invertebrate test species
for environmental risk assessment
The ERA of a human medical product within a market-
ing application requires tests on three species, representing
different trophic levels. The invertebrate most commonly
used is a daphnid species. Toxicity testing with Daphnia
may, however, not be protective of other invertebrates if or-
thologs to the drug targets are absent inDaphnia but present
in other invertebrate species. The ECOdrug database en-
ables quick identification of such cases. To illustrate this,
the ECOdrug predictions suggest that orthologs of the thy-
roid hormone receptors (THRA/THRB) are not present in
Daphnia pulex, but do occur in some invertebrate deuteros-
tomes (such as the sea urchin) and molluscs. These results
align with a recent review on thyroid signaling conservation
describing the presence of thyroid hormone receptors in
invertebrate deuterostomes and nematodes––though they
are not always responsive to thyroid hormone (29). In hu-
mans, defects in thyroid hormone signaling can lead to se-
vere pathological conditions (30). The role of thyroid sig-
naling in the invertebrates is not well understood and more
research is required both to understand the basic biological
process involved and thus the potential for drugs such as
levothyroxine and liothyronine to affect invertebrates pos-
sessing orthologs of the thyroid hormone receptors.
Case study III: selecting appropriate species for environmen-
tal protection of primary producers
Cholesterol lowering drugs, also known as statins, are
commonly prescribed and they include atorvastatin, lovas-
tatin and rosuvastatin. These statins target 3-hydroxy-3-
methylglutaryl Coenzyme A Reductase (HMG-CoA Re-
ductase; HMGCR), the rate limiting enzyme in the
mevalonate pathway, responsible for cholesterol synthesis.
HMGCR is ubiquitous amongst eukaryotes and prokary-
otes (31). In ERA primary producers are most often rep-
resented by a green algal species but results from ECOdrug
indicate that in the case for statins other primary producers,
e.g. plants, may be more appropriate for testing. ECOdrug
illustrates that green algae species (chlorophytes) lack or-
thologs to HMGCR while higher plants have an HMGCR
ortholog (Figure 5), a prediction that is in agreement with
recent assessments of the molecular evolution of HMGCR
(32). Further supporting this assumption, duckweedLemna
gibba has been reported to be at least 100 times more sen-
sitive than green algae Chlamydomonas reinhardtii (24 000
g/L) (33) to atorvastatin exposure (34). The toxicity for
atorvastatin in L. gibba is in the same concentration range
as its toxicity in daphnia (140 g/L) and fish (450 g/L)
(33). Collectively, these results suggest that statins toxicity
in plants is related to inhibition of HMGCR and indicate
that toxicity tests in aquatic plants (or diatoms, or red al-
gae)may bemore protective of primary producers than tests
with green algae.
FUTURE DIRECTIONS
We propose to further improve ECOdrug through integra-
tion with other platforms. First, with iPiEsys, a predictive
framework that uses information from existing datasets on
environmental fate and effects of APIs, toxicological stud-
ies, pharmacological mode of action and in silicomodels to
support more intelligent environmental testing of pharma-
ceuticals. This is being developed by an InnovativeMedicine
Initiative EU consortium (http://i-pie.org/). Second, an ini-
tiative to develop evidence based tool to support the reduc-
tion, refinement and replacement of animals for experimen-
tation (3Rs) for the ERA of pharmaceuticals is underway.
The Virtual Fish Ecotoxicology Laboratory will use ECO-
drug to help drive intelligent testing strategies that iden-
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Figure 5. ECODrug application: drug target page. The drug target page displays two sets of information for any given drug target. A graphic display of
drug target conservation across taxonomic groups is shown in (A) with numbers based on species shared between all three prediction methods. Species
specific ortholog predictions for combined and individual ortholog predictions methods are shown in a table (B).
tify which fish species should be used for effect and bioac-
cumulation studies based on the presence of targets (http:
//www.simomics.com/). In addition, we aim to providemore
detailed information regarding potential for binding of a
drug to a drug target ortholog, for example in the form of
binding site conservation. ECOdrug presents ortholog pre-
dictions for therapeutic drug targets only, but this can be ex-
panded to include a wider set of proteins that are known to
interact with drugs for example transporters andmetabolis-
ing enzymes etc. The therapeutic score can also be widened
to include antimicrobials and antiparasitics. Through inte-
grationwith the systems outlined above, the addition of new
features and regular updating we aim to ensure ECOdrug is
maintained as a valuable and contemporary research tool
for the communities in drug discovery, comparative and
evolutionary biology and (eco)toxicology.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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